Medicare Enrolled
Dr. Ziad Khan, M.D.
Hematology · Rancho Cucamonga, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Khan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Khan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Khan
Dr. Ziad Khan is a hematology specialist in Rancho Cucamonga, CA, with 15 years of NPI registration. Based on federal Medicare data, Dr. Khan performed 562 Medicare services across 284 unique beneficiaries.
Between the years covered by Open Payments, Dr. Khan received a total of $37,522 from 87 pharmaceutical and/or device companies across 1493 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Khan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years in practice
▲ Top 43% volume in CA
$37,522 industry payments
Medicare Practice Summary
Medicare Utilization ↗562
Medicare services
Top 43% in CA for hematology
284
Unique beneficiaries
$73
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~37 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
257 | $62 | $280 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
112 | $75 | $268 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
84 | $47 | $173 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
64 | $136 | $631 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
29 | $99 | $451 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
16 | $93 | $422 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$37,522
Total received (2018-2024)
Avg $5,360/year across 7 years
Top 28% in CA for hematology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
87
Companies
1,493
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$26,921 (71.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$10,601 (28.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$15,179
2023
$4,823
2022
$4,491
2021
$3,442
2020
$2,958
2019
$3,844
2018
$2,785
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$10,026
Merck Sharp & Dohme LLC
$497
Novartis Pharmaceuticals Corporation
$455
Janssen Biotech, Inc.
$341
AstraZeneca Pharmaceuticals LP
$292
E.R. Squibb & Sons, L.L.C.
$285
Genentech USA, Inc.
$252
Astellas Pharma US Inc
$217
Eisai Inc.
$202
Aveo Pharmaceuticals, Inc.
$199
BeiGene USA, Inc.
$194
Celgene Corporation
$180
Lilly USA, LLC
$149
ARRAY BIOPHARMA INC
$141
Dendreon Pharmaceuticals LLC
$124
Regeneron Healthcare Solutions, Inc.
$118
ADC Therapeutics America, Inc.
$114
SOBI, INC
$108
ABBVIE INC.
$103
Tempus AI, Inc
$93
PUMA BIOTECHNOLOGY, INC.
$79
Boehringer Ingelheim Pharmaceuticals, Inc.
$74
SpringWorks Therapeutics, Inc.
$74
Sumitomo Pharma America, Inc.
$64
Gilead Sciences, Inc.
$59
Takeda Pharmaceuticals U.S.A., Inc.
$58
Exelixis Inc.
$55
GENZYME CORPORATION
$53
Daiichi Sankyo Inc.
$53
Incyte Corporation
$53
GlaxoSmithKline, LLC.
$52
Menarini Silicon Biosystems, Inc.
$52
EMD Serono, Inc.
$52
Adaptive Biotechnologies Corporation
$46
Ipsen Biopharmaceuticals, Inc
$43
TAIHO ONCOLOGY, INC.
$40
Bayer Healthcare Pharmaceuticals Inc.
$35
Immunocore Limited
$29
Legend Biotech USA Inc.
$27
Kite Pharma, Inc.
$22
Acrotech Biopharma Inc.
$21
SERVIER PHARMACEUTICALS LLC
$19
Agios Pharmaceuticals, Inc.
$17
Janssen Pharmaceuticals, Inc
$15
Top 3 companies account for 72.3% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$11,432
Novartis Pharmaceuticals Corporation
$2,506
E.R. Squibb & Sons, L.L.C.
$1,934
Janssen Biotech, Inc.
$1,567
Genentech USA, Inc.
$1,195
Merck Sharp & Dohme LLC
$1,174
AstraZeneca Pharmaceuticals LP
$1,144
Celgene Corporation
$1,086
Amgen Inc.
$1,019
GENZYME CORPORATION
$952
Incyte Corporation
$837
Merck Sharp & Dohme Corporation
$789
Astellas Pharma US Inc
$760
Boehringer Ingelheim Pharmaceuticals, Inc.
$535
GlaxoSmithKline, LLC.
$500
BeiGene USA, Inc.
$439
Gilead Sciences, Inc.
$438
Bayer HealthCare Pharmaceuticals Inc.
$436
Lilly USA, LLC
$435
Eisai Inc.
$428
Regeneron Healthcare Solutions, Inc.
$413
Exelixis Inc.
$397
Takeda Pharmaceuticals U.S.A., Inc.
$352
Alexion Pharmaceuticals, Inc.
$325
ARRAY BIOPHARMA INC
$295
Dendreon Pharmaceuticals LLC
$294
Seagen Inc.
$293
Pharmacyclics LLC, An AbbVie Company
$263
TESARO, Inc.
$247
Puma Biotechnology, Inc.
$246
AVEO Pharmaceuticals, Inc.
$241
EMD Serono, Inc.
$232
Kite Pharma, Inc.
$228
Aveo Pharmaceuticals, Inc.
$228
Myovant Sciences Inc.
$227
SOBI, INC
$226
Karyopharm Therapeutics Inc.
$206
SANOFI-AVENTIS U.S. LLC
$200
Dova Pharmaceuticals
$194
Ipsen Biopharmaceuticals, Inc
$159
Janssen Pharmaceuticals, Inc
$156
Sumitomo Pharma America, Inc.
$148
PUMA BIOTECHNOLOGY, INC.
$147
Bayer Healthcare Pharmaceuticals Inc.
$121
Daiichi Sankyo Inc.
$121
ADC Therapeutics America, Inc.
$114
Global Blood Therapeutics, Inc.
$111
Taiho Oncology, Inc.
$103
ABBVIE INC.
$103
Tempus AI, Inc
$93
Sobi, Inc
$93
EISAI INC.
$89
Mylan Institutional Inc.
$82
Teva Pharmaceuticals USA, Inc.
$81
TAIHO ONCOLOGY, INC.
$77
SpringWorks Therapeutics, Inc.
$74
Seattle Genetics, Inc.
$73
SERVIER PHARMACEUTICALS LLC
$67
Myriad Genetic Laboratories, Inc.
$55
Terumo BCT, Inc.
$53
Menarini Silicon Biosystems, Inc.
$52
Foundation Medicine, Inc.
$46
Adaptive Biotechnologies Corporation
$46
Mirati Therapeutics, Inc.
$44
INSYS Therapeutics Inc
$44
TOLMAR Pharmaceuticals, Inc.
$35
Agios Pharmaceuticals, Inc.
$32
Immunomedics, Inc.
$30
Immunocore Limited
$29
Blueprint Medicines Corporation
$27
Legend Biotech USA Inc.
$27
Clovis Oncology, Inc.
$25
Rigel Pharmaceuticals, Inc.
$24
TG Therapeutics, Inc.
$23
PharmaEssentia USA Corporation
$22
AMAG Pharmaceuticals, Inc.
$22
Acrotech Biopharma Inc.
$21
Stemline Therapeutics Inc.
$20
Pharmacyclics LLC, an AbbVie Company
$18
NOVARTIS PHARMACEUTICALS CORPORATION
$18
R-Pharm US LLC
$17
Novo Nordisk Inc
$16
Deciphera Pharmaceuticals Inc.
$15
Epizyme, Inc.,
$13
Emmaus Medical, Inc.
$13
BTG International, Inc.
$11
SECURA BIO, INC.
$1
Top 3 companies account for 42.3% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADAKVEO · ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BALVERSA · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABOMETYX · CALQUENCE · CARVYKTI · COPIKTRA · CYRAMZA · Cabometyx · Cellsearch · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · Endari · Enhertu · Erleada · Esperoct · FASLODEX · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAZYVA · GILOTRIF · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · INREBIC · Imbruvica · Inrebic · Itovebi · Ixempra · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MVASI · MYCHOICE CDX · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OGIVRI · OGSIVEO · ONUREG · OPDIVO · ORGOVYX · OXBRYTA · Ogivri · Onivyde · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Polivy · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · RYDAPT · Rituxan Hycela · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SUTENT · SYNDROS · Spectra Optia Apheresis System · Stivarga · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · Tavalisse · Tazverik · Tecentriq · Tibsovo · Trodelvy · UKONIQ · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VORAXAZE · VOTRIENT · Vectibix · Venclexta · Vyloy · XALKORI · XARELTO · XGEVA · XPOVIO · XTANDI · XYNTHA · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · Zydelig · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (72%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematologists within 10 mi
22
Per 100K population
1.0
County median income
$82,184
Nearest hospital
SAN ANTONIO REGIONAL HOSPITAL
4.8 mi
4.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Khan is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 15 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Khan experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Khan performed 257 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Khan receive payments from pharmaceutical companies?
Yes. Dr. Khan received a total of $37,522 from 87 companies across 1,493 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Khan's costs compare to other hematologists in Rancho Cucamonga?
Dr. Khan's average Medicare payment per service is $73. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Khan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologists in Rancho Cucamonga
Browse hematologists in Rancho Cucamonga ranked by procedure volume and transparency data.
Highest volume
Top Hematologists in CA
Hematologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologists in CA
Which CA hematologists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology